NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What is the boxed warning for Tocilizumab and Sarilumab?

May cause liver damage
Serious infections and screen for TB
May cause heart failure
Serious skin reactions

The correct answer is: Serious infections and screen for TB

Tocilizumab and Sarilumab are medications that are used to treat inflammatory conditions such as rheumatoid arthritis. These drugs block the action of a protein called IL-6, which has been linked to inflammation. Both Tocilizumab and Sarilumab carry a boxed warning, which is the strongest warning given by the FDA. This warning is placed on medications that have a serious risk of potentially life-threatening side effects. The boxed warning for Tocilizumab and Sarilumab is about serious infections. These medications can weaken the body's immune system, making it easier for infections to occur. It is important for patients taking these medications to be closely monitored for signs of infection, and to be screened for tuberculosis before starting treatment. The other options are incorrect because they do not reflect the boxed warning for Tocilizumab and Sarilumab. While these medications may have potential side effects such as liver damage, heart failure, and serious skin reactions, the boxed warning specifically mentions serious infections. Therefore, B is the correct option and the most important warning for patients and healthcare providers to be aware of when using Tocilizumab and Sarilumab.